Anoro Umeclidinium Bromide and Vilanterol Trifenatate Powder for Oral Inhalation

1. Indications and Usage
COPD Maintenance: Indicated for the once-daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD).
Usage Restrictions: Not indicated for the relief of acute bronchospasm (i.e., it is not a rescue inhaler). It is not recommended for the treatment of asthma.
2. Dosage and Administration
Route of Administration: For oral inhalation ONLY.
Recommended Dosage: One inhalation of 62.5 mcg umeclidinium and 25 mcg vilanterol once daily, administered at approximately the same time every day. Do not exceed the maximum recommended dose of one inhalation daily.
Critical Administration Instructions:
Device Handling: Use only with the approved dry powder inhaler device (e.g., ELLIPTA). Do not shake the inhaler.
Loading and Inhaling: Breath out fully away from the inhaler. Place lips tightly around the mouthpiece and breathe in deeply and forcefully. Hold breath for ~10 seconds. Slide green lever to load the next dose.
Oral Hygiene: Rinse mouth with water without swallowing after use to reduce the risk of oral candidiasis.
3. Mechanism of Action
LAMA Activity: Umeclidinium is a long-acting muscarinic antagonist (LAMA) that competitively inhibits acetylcholine at muscarinic M3 receptors on airway smooth muscle, causing bronchodilation.
LABA Activity: Vilanterol is a long-acting selective beta2-adrenergic agonist (LABA) that activates beta2 receptors, increasing intracellular cAMP and relaxing bronchial smooth muscle.
Synergistic Effect: The combination provides complementary and sustained bronchodilation for 24 hours.
4. Safety and Warnings
Paradoxical Bronchospasm: If bronchospasm occurs after administration, discontinue immediately and initiate alternative therapy.
Cardiovascular Effects: May cause dose-related increases in heart rate, blood pressure, and cardiovascular events (e.g., atrial fibrillation, palpitations).
Hypersensitivity: Hypersensitivity reactions, including angioedema, anaphylaxis, and rash, have been reported.
Lactose Intolerance: The formulation contains lactose; use with caution in patients with severe milk protein allergies.
Glaucoma and Urinary Retention: Use with caution in patients with narrow-angle glaucoma and those at risk of urinary retention.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: Nasopharyngitis, upper respiratory tract infection, sinusitis, back pain, and hypertension.
Other Adverse Reactions: Oral candidiasis, dry mouth, cough, throat irritation, and tremor.
Clinical Research Highlights: Phase III trials demonstrated significant improvements in lung function (FEV1) and reduction in COPD exacerbation rates compared to monotherapy components or placebo.
6. Drug Interactions
Beta-Blockers: Non-selective beta-blockers may antagonize the effects of vilanterol and should be avoided unless there is a compelling clinical reason to use them.
QT-Prolonging Drugs: Concomitant use with drugs known to prolong the QT interval should be approached with caution.
Other Bronchodilators: Do not use concurrently with other long-acting muscarinic antagonists (LAMA) or long-acting beta2-agonists (LABA) due to increased risk of adverse reactions.
CYP3A4 Inhibitors: Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase the systemic exposure of vilanterol, though clinical impact at therapeutic doses is low.
7. Pharmaceutical Information
Chemical Composition: Umeclidinium bromide and Vilanterol trifenatate.
Appearance: White powder enclosed in individual blisters within a foil strip, housed in a dry powder inhaler device.
Packaging: Typically supplied as 30-dose inhalers.
Storage: Store in the sealed outer carton to protect from moisture. Use within 6 weeks after removing from the foil strip; discard 6 weeks after first opening, even if doses remain.